Saltar al contenido principal


Cursos disponibles

Imagen del curso
Cursos vinculados
401. Blood Transfusion: Poster I, 401. Blood Transfusion: Poster II, 401. Blood Transfusion: Poster III, 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I, 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II, 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III, 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I, 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II, 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III, 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster I, 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster II, 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster III, 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster I, 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster II, 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III, 621. Lymphomas: Translational Molecular and Genetic: Poster I, 621. Lymphomas: Translational Molecular and Genetic: Poster II, 621. Lymphomas: Translational Molecular and Genetic: Poster III, 622. Lymphomas: Translational Non-Genetic: Poster I, 622. Lymphomas: Translational Non-Genetic: Poster II, 622. Lymphomas: Translational Non-Genetic: Poster III, 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I, 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II, 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III, 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I, 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster II, 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster III, 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster I, 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster II, 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III, 626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Poster I, 626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Poster II, 626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Poster III, 627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster I, 627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster II, 627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster III, 628. Aggressive Lymphomas: Cellular Therapies: Poster I, 628. Aggressive Lymphomas: Cellular Therapies: Poster II, 628. Aggressive Lymphomas: Cellular Therapies: Poster III, 629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster I, 629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster II, 629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster III, 641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster I, 641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster II, 641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster III, 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I, 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II, 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III, 909. Education, Communication, and Workforce: Poster I, 909. Education, Communication, and Workforce: Poster II, 909. Education, Communication, and Workforce: Poster III
Imagen del curso
Cursos vinculados
401. Blood Transfusion: Poster I, 401. Blood Transfusion: Poster II, 401. Blood Transfusion: Poster III, 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I, 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II, 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III, 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster I, 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II, 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III, 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I, 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II, 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III, 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I, 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II, 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III, 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster I, 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster II, 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster III, 619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster I, 619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster II, 619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster III, 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I, 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II, 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III, 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I, 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II, 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III, 636. Myelodysplastic Syndromes: Basic and Translational: Poster I, 636. Myelodysplastic Syndromes: Basic and Translational: Poster II, 636. Myelodysplastic Syndromes: Basic and Translational: Poster III, 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I, 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II, 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III, 908. Outcomes Research: Myeloid Malignancies: Poster I, 908. Outcomes Research: Myeloid Malignancies: Poster II, 908. Outcomes Research: Myeloid Malignancies: Poster III, 909. Education, Communication, and Workforce: Poster I, 909. Education, Communication, and Workforce: Poster II, 909. Education, Communication, and Workforce: Poster III
Imagen del curso
Imagen del curso
Cursos vinculados
301. Platelets and Megakaryocytes: Basic and Translational: Poster I, 301. Platelets and Megakaryocytes: Basic and Translational: Poster II, 301. Platelets and Megakaryocytes: Basic and Translational: Poster III, 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I, 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II, 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III, 321. Coagulation and Fibrinolysis: Basic and Translational: Poster I, 321. Coagulation and Fibrinolysis: Basic and Translational: Poster II, 321. Coagulation and Fibrinolysis: Basic and Translational: Poster III, 322. Hemophilia A and B: Clinical and Epidemiological: Poster I, 322. Hemophilia A and B: Clinical and Epidemiological: Poster II, 322. Hemophilia A and B: Clinical and Epidemiological: Poster III, 331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster I, 331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster II, 331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster III, 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I, 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II, 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III, 401. Blood Transfusion: Poster I, 401. Blood Transfusion: Poster II, 401. Blood Transfusion: Poster III, 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster I, 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster II, 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster III, 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster I, 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster II, 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster III, 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster I, 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster II, 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster III, 909. Education, Communication, and Workforce: Poster I, 909. Education, Communication, and Workforce: Poster II, 909. Education, Communication, and Workforce: Poster III
Imagen del curso
Cursos vinculados
101. Red Cells and Erythropoiesis, Excluding Iron: Poster I, 101. Red Cells and Erythropoiesis, Excluding Iron: Poster II, 101. Red Cells and Erythropoiesis, Excluding Iron: Poster III, 102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster I, 102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster II, 102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster III, 112. Thalassemia and Globin Gene Regulation: Poster I, 112. Thalassemia and Globin Gene Regulation: Poster II, 112. Thalassemia and Globin Gene Regulation: Poster III, 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster I, 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster II, 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster III, 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster I, 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster II, 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III, 401. Blood Transfusion: Poster I, 401. Blood Transfusion: Poster II, 401. Blood Transfusion: Poster III, 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I, 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II, 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III, 909. Education, Communication, and Workforce: Poster I, 909. Education, Communication, and Workforce: Poster II, 909. Education, Communication, and Workforce: Poster III
Imagen del curso
Cursos vinculados
401. Blood Transfusion: Poster I, 401. Blood Transfusion: Poster II, 401. Blood Transfusion: Poster III, 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster I, 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster II, 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster III, 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I, 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II, 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III, 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster I, 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster II, 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster III, 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster I, 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster II, 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster III, 904. Outcomes Research: Hemoglobinopathies: Poster I, 904. Outcomes Research: Hemoglobinopathies: Poster II, 904. Outcomes Research: Hemoglobinopathies: Poster III, 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I, 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II, 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III, 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I, 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II, 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III, 907. Outcomes Research: Plasma Cell Disorders: Poster I, 907. Outcomes Research: Plasma Cell Disorders: Poster II, 907. Outcomes Research: Plasma Cell Disorders: Poster III, 908. Outcomes Research: Myeloid Malignancies: Poster I, 908. Outcomes Research: Myeloid Malignancies: Poster II, 908. Outcomes Research: Myeloid Malignancies: Poster III, 909. Education, Communication, and Workforce: Poster I, 909. Education, Communication, and Workforce: Poster II, 909. Education, Communication, and Workforce: Poster III
Imagen del curso
Cursos vinculados
201. Granulocytes, Monocytes, and Macrophages: Poster I, 201. Granulocytes, Monocytes, and Macrophages: Poster II, 201. Granulocytes, Monocytes, and Macrophages: Poster III, 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I, 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II, 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III, 401. Blood Transfusion: Poster I, 401. Blood Transfusion: Poster II, 401. Blood Transfusion: Poster III, 701. Experimental Transplantation: Basic and Translational: Poster I, 701. Experimental Transplantation: Basic and Translational: Poster II, 701. Experimental Transplantation: Basic and Translational: Poster III, 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster I, 703. Cellular Immunotherapies other than CAR-T Cells: Poster II, 703. Cellular Immunotherapies other than CAR-T Cells: Poster III, 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I, 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II, 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III, 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster I, 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster II, 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster III, 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster I, 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster II, 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III, 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I, 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster II, 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III, 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster I, 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster II, 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster III, 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I, 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II, 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III, 909. Education, Communication, and Workforce: Poster I, 909. Education, Communication, and Workforce: Poster II, 909. Education, Communication, and Workforce: Poster III
Imagen del curso
Cursos vinculados
401. Blood Transfusion: Poster I, 401. Blood Transfusion: Poster II, 401. Blood Transfusion: Poster III, 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I, 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II, 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III, 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I, 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II, 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III, 653. Multiple Myeloma: Clinical and Epidemiological: Poster I, 653. Multiple Myeloma: Clinical and Epidemiological: Poster II, 653. Multiple Myeloma: Clinical and Epidemiological: Poster III, 654. Multiple Myeloma: Pharmacologic Therapies: Poster I, 654. Multiple Myeloma: Pharmacologic Therapies: Poster II, 654. Multiple Myeloma: Pharmacologic Therapies: Poster III, 655. Multiple Myeloma: Cellular Therapies: Poster I, 655. Multiple Myeloma: Cellular Therapies: Poster II, 655. Multiple Myeloma: Cellular Therapies: Poster III, 907. Outcomes Research: Plasma Cell Disorders: Poster I, 907. Outcomes Research: Plasma Cell Disorders: Poster II, 907. Outcomes Research: Plasma Cell Disorders: Poster III, 909. Education, Communication, and Workforce: Poster I, 909. Education, Communication, and Workforce: Poster II, 909. Education, Communication, and Workforce: Poster III
Imagen del curso
Cursos vinculados
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I, 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II, 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III, 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I, 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II, 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III, 614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I, 614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II, 614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III, 618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I, 618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II, 618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III, 621. Lymphomas: Translational – Molecular and Genetic: Poster I, 621. Lymphomas: Translational—Molecular and Genetic: Poster II, 621. Lymphomas: Translational—Molecular and Genetic: Poster III, 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I, 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II, 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III, 624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Poster I, 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster II, 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster III, 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I, 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster II, 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III, 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster I, 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II, 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster III, 641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster I, 641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster II, 641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster III, 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I, 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II, 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III, 622. Lymphomas: Translational–Non-Genetic: Poster II, 622. Lymphomas: Translational–Non-Genetic: Poster III, 622. Lymphomas: Translational – Non-Genetic: Poster I
Imagen del curso
Cursos vinculados
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I, 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II, 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III, 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I, 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II, 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III, 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I, 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II, 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III, 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I, 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II, 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III, 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I, 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II, 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III, 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I, 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II, 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III, 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I, 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III, 636. Myelodysplastic Syndromes – Basic and Translational: Poster I, 636. Myelodysplastic Syndromes—Basic and Translational: Poster II, 636. Myelodysplastic Syndromes—Basic and Translational: Poster III, 637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster I, 637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster II, 637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster III, 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II
Imagen del curso
Cursos vinculados
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster I, 301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster II, 301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster III, 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I, 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II, 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III, 321. Coagulation and Fibrinolysis: Basic and Translational: Poster I, 321. Coagulation and Fibrinolysis: Basic and Translational: Poster II, 321. Coagulation and Fibrinolysis: Basic and Translational: Poster III, 322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster I, 322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II, 322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster III, 331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-Related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster I, 331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster II, 331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster III, 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I, 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II, 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III
Imagen del curso
Cursos vinculados
101. Red Cells and Erythropoiesis, Excluding Iron: Poster I, 101. Red Cells and Erythropoiesis, Excluding Iron: Poster II, 101. Red Cells and Erythropoiesis, Excluding Iron: Poster III, 102. Iron Homeostasis and Biology: Poster I, 102. Iron Homeostasis and Biology: Poster II, 102. Iron Homeostasis and Biology: Poster III, 112. Thalassemia and Globin Gene Regulation: Poster I, 112. Thalassemia and Globin Gene Regulation: Poster II, 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster I, 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster II, 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster III, 114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster I, 114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster II, 114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III, 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I, 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II, 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III, 112. Thalassemia and Globin Gene Regulation: Poster III
Imagen del curso
Cursos vinculados
201. Granulocytes, Monocytes, and Macrophages: Poster I, 201. Granulocytes, Monocytes, and Macrophages: Poster II, 201. Granulocytes, Monocytes, and Macrophages: Poster III, 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I, 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II, 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III, 701. Experimental Transplantation: Basic and Translational: Poster I, 701. Experimental Transplantation: Basic and Translational: Poster II, 701. Experimental Transplantation: Basic and Translational: Poster III, 703. Cellular Immunotherapies: Basic and Translational: Poster I, 703. Cellular Immunotherapies: Basic and Translational: Poster II, 703. Cellular Immunotherapies: Basic and Translational: Poster III, 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I, 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster II, 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III, 711. Cell Collection and Processing: Poster I, 711. Cell Collection and Processing: Poster II, 711. Cell Collection and Processing: Poster III, 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I, 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II, 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster III, 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I, 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II, 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III, 723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Poster I, 723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster II, 723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster III, 731. Autologous Transplantation: Clinical and Epidemiological: Poster I, 731. Autologous Transplantation: Clinical and Epidemiological: Poster II, 731. Autologous Transplantation: Clinical and Epidemiological: Poster III, 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I, 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II, 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III, 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster I, 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II, 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III
Imagen del curso
Cursos vinculados
Platelets mediate the clearance of senescent red blood cells by forming pro-phagocytic platelet-cell complexes, Genomic Landscape of Patients with Germline RUNX1 Variants and Familial Platelet Disorder with Myeloid Malignancy, Regulation of lymphoid-myeloid lineage bias through Regnase-1/3-mediated control of Nfkbiz, First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis, Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progression, Less-deformable erythrocyte subpopulations biomechanically induce endothelial inflammation in sickle cell disease, DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma, Clearance of VWF by hepatic macrophages is critical for the protective effect of ADAMTS13 in sickle cell anemia mice, Low-density lipoprotein promotes microvascular thrombosis by enhancing von Willebrand factor self-association, Modeling and Targeting of Erythroleukemia by Hematopoietic Genome Editing, CRISPR-Edited Megakaryocytes for Rapid Screening of Platelet Gene Functions, Assembly of Alternative Prothrombinase by Extracellular Histones Initiates and Disseminates Intravascular Coagulation, IL-1 Mediates Microbiome-Induced Inflammaging of Hematopoietic Stem Cells in Mice, A STAT5B–CD9 Axis Determines Self-Renewal in Hematopoietic and Leukemic Stem Cells, Hypofibrinogenemia with Preserved Hemostasis and Protection from Thrombosis in Mice with an Fga Truncation Mutation, IL-13/IL-4 Signaling Contributes to Fibrotic Progression of the Myeloproliferative Neoplasms, Endothelial Cell–Leukemia Interactions Remodel Drug Responses, Uncovering T-ALL Vulnerabilities, IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells, Structural Basis of MPL Activation by Thrombopoietin, Adaptation to Ex Vivo Culture Reduces Human Hematopoietic Stem Cell Activity Independently of the Cell Cycle, An Inducible Cd79b Mutation Confers Ibrutinib Sensitivity in Mouse Models of Myd88-Driven Diffuse Large B-cell Lymphoma, Novel Machine Learning Technique Further Clarifies Unrelated Donor Selection to Optimize Transplantation Outcomes, Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma
Ver detalle
07/04/2025 To 07/04/2026
Classical hematology
Ver detalle
07/05/2025 To 07/05/2026
Acute Myeloid Leukemia Clonal myeloid disorders Emerging technologies Research - Basic Science Research - Clinical Research - Pre-Clinical Models Research - Translational Treatment-related acute myeloid leukemia
Ver detalle
07/05/2025 To 07/05/2026
Grant writing Hematology workforce Interdisciplinary collaboration Medical education Non-human populations - Animal models Peer-reviewed articles/publications Research - Basic Science Research - Biostatistics Research - Clinical Research - Outcomes Research - Population Science Research - Pre-Clinical Models Research - Translational Systems-based hematology Underserved populations
Ver detalle
11/19/2019
Acquired iron overload states Acquired thrombophilias Adverse effects of transfusion Autoimmune aplastic anemia and other acquired bone Basics of transfusion medicine Clinical indications for transfusion Clinical practice Delayed non-immune Guidelines Health disparities Hematopathology Hematopoiesis and bone marrow failure syndromes Hematopoietic stem cell transplantation Human population Inherited anemias Iron physiology and iron overload syndromes Microvascular thrombosis Normal red cell physiology Other topics in classical hematology Patient experience Racial and ethnic minorities Red cell disorders Sickle cell disease Sickle cell disorders Supportive Care Targeted therapy Thalassemias Therapeutics Thrombotic disorders Transfusion medicine and apheresis Transfusion support in hematologic disorders Treating fairly Underserved populations
Ver detalle
10/04/2025 To 10/04/2026
Grant writing Medical education Pre-clinical models Research - Biostatistics Research - Clinical Research - Outcomes Research - Population Science
Ver detalle
02/24/2021
Research - Biostatistics Research - Clinical Research - Grant writing Research - Pre-Clinical Models
Ver detalle
12/12/2021
Adoptive cellular therapies Allogeneic hematopoietic stem cell transplantation Chimeric antigen receptor T-cell therapies Health disparities Hematopoietic stem cell transplantation Research - Population Science Treating fairly
Ver detalle
02/24/2020 To 02/24/2027
CRTI application Medical education Research - Biostatistics Research - Clinical Research - Grant writing
Ver detalle
08/01/2020 To 02/24/2027
Research - Grant writing